Reduces oxidative stress and immune activation Promotes vascular repair in inflamed tissue May help maintain remission alongside standard therapies BPC-157 therapy in colitis models improved mucosal appearance, weight retention, and reduced systemic inflammation markers. Tkalcevic, V
Geriatric use: Elderly patients may be more sensitive to NSAIDs, so it is recommended to use the lowest effective dose
Across Achilles tendon detachment [1] , medial collateral ligament transection [4] , myotendinous junction separation [14] , gastric ulcer models [5] , colocutaneous fistula models [6] , spinal cord compression injury [10] , and several CNS perturbation paradigms [11] , administered BPC-157 consistently outperformed untreated controls on the relevant outcome measures
It is critical to note that the safety profile for injectable or systemic use is far less established due to a lack of human research